Cargando…

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration

Adoptive cellular therapy has made a landmark change within the treatment paradigm of several hematologic malignancies, and novel cellular therapy products, such as chimeric antigen receptor T‐cell therapy (CART), have demonstrated impressive efficacy and produced durable responses. However, the CAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatwood, Katie S., Dholaria, Bhagirathbhai R., Lucena, Mariana, Baer, Brittney, Savani, Bipin N., Oluwole, Olalekan O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176074/ https://www.ncbi.nlm.nih.gov/pubmed/35844300 http://dx.doi.org/10.1002/jha2.333

Ejemplares similares

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
por: Bachanova, Veronika, et al.
Publicado: (2020)

Securing the graft during pandemic: are we ready for cryopreservation for all?
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

The Essentials of Drug Interactions in Hematopoietic Stem Cell Transplantation
por: Gatwood, Katie S., et al.
Publicado: (2019)

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation
por: Yuda, Sayako, et al.
Publicado: (2022)

The Recurring Problem of Drug Shortages—How Do We Overcome It?
por: Gupta, Rishabh, et al.
Publicado: (2019)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

Next generation of immune checkpoint therapy in cancer: new developments and challenges
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Emerging therapeutic agents for lung cancer
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2016)

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
por: Mangan, Brendan L., et al.
Publicado: (2020)

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
por: Hu, Jiun-Ruey, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
por: Han, Ethan Q, et al.
Publicado: (2013)

Chimeric antigen receptor T cell therapies for thoracic cancers—challenges and opportunities
por: Chan, Jack D., et al.
Publicado: (2020)

Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges
por: Toulouie, Sara, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
por: Xiao, Bu-Fan, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
por: Xu, Caili, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis
por: Hunter, Bradley D., et al.
Publicado: (2022)

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
por: Xia, An-Liang, et al.
Publicado: (2017)

Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2017)

Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy
por: Bogetofte Barnkob, Mike, et al.
Publicado: (2022)

Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions
por: Zhang, Peng, et al.
Publicado: (2022)

Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care
por: Snyder, Sophie, et al.
Publicado: (2021)

Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2022)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
por: Mohty, Mohamad, et al.
Publicado: (2020)

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
por: Geethakumari, Praveen Ramakrishnan, et al.
Publicado: (2021)

Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2019)

Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
por: Springuel, Lorraine, et al.
Publicado: (2019)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
por: Soltantoyeh, Tahereh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i2tgikn2v79fbiicn5nrkhscpp